ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,475.09
      0.27%
      US Tech 100
      19,199.60
      -0.40%
      Dow Jones
      39,169.52
      0.13%
      Brent Oil
      86.84
      0.36%
      Bitcoin
      62,625.73
      -0.36%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Verastem Inc (VSTM)

      7. Verastem Inc (VSTM) News

      VSTM

      Verastem (VSTM)

      Verastem Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:VSTM
      DateTimeSourceHeadlineSymbolCompany
      12/19/20234:01PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:VSTMVerastem Inc
      12/18/20237:00AMBusiness WireVerastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet TherapeuticsNASDAQ:VSTMVerastem Inc
      12/13/20237:00AMBusiness WireVerastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian CancerNASDAQ:VSTMVerastem Inc
      12/08/20234:10PMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:VSTMVerastem Inc
      11/21/202312:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:VSTMVerastem Inc
      11/13/20237:00AMBusiness WireNew Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment ApproachNASDAQ:VSTMVerastem Inc
      11/08/20235:01PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:VSTMVerastem Inc
      11/08/20234:16PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VSTMVerastem Inc
      11/08/20234:12PMBusiness WireVerastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:VSTMVerastem Inc
      11/07/20237:00AMBusiness WireFirst-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian CancerNASDAQ:VSTMVerastem Inc
      11/06/20237:00AMBusiness WireVerastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient PopulationNASDAQ:VSTMVerastem Inc
      10/27/20234:41PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VSTMVerastem Inc
      10/26/20234:28PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VSTMVerastem Inc
      10/26/20234:05PMBusiness WireVerastem Oncology Strengthens Executive Leadership Team with Key AppointmentsNASDAQ:VSTMVerastem Inc
      10/18/20234:50PMBusiness WireVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VSTMVerastem Inc
      10/14/202312:30PMBusiness WireVerastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung CancerNASDAQ:VSTMVerastem Inc
      10/10/20234:31PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VSTMVerastem Inc
      10/06/20237:00AMBusiness WireVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VSTMVerastem Inc
      09/28/20232:27PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VSTMVerastem Inc
      09/28/20232:15PMBusiness WireVerastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development SummitNASDAQ:VSTMVerastem Inc
      09/25/20234:46PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VSTMVerastem Inc
      09/20/20234:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VSTMVerastem Inc
      09/20/20234:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VSTMVerastem Inc
      09/12/20234:08PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VSTMVerastem Inc
      09/05/20237:00AMBusiness WireVerastem Oncology to Participate in Upcoming Investor ConferencesNASDAQ:VSTMVerastem Inc
      08/28/20237:00AMBusiness WireVerastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven CancersNASDAQ:VSTMVerastem Inc
      08/08/20234:16PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VSTMVerastem Inc
      08/08/20234:05PMBusiness WireVerastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:VSTMVerastem Inc
      08/04/20234:40PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VSTMVerastem Inc
      08/04/20234:40PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:VSTMVerastem Inc
       Showing the most relevant articles for your search:NASDAQ:VSTM